NCT07085117View on ClinicalTrials.gov

Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients

CompletedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

August 10, 2025

Study Completion Date

August 10, 2025

Conditions
Thyroid Eye Disease
Interventions
DRUG

Teprotumumab

Participants received teprotumumab as an intravenous (IV) infusion.

Trial Locations (1)

571400

Boao Vanguard Hospital, Qionghai

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY